Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches.

The rationale for this is based on animal models suggesting that statins can attenuate organ dysfunction by reducing vascular leak and inflammation.[ 84 ] A prospective cohort study in Ireland showed a nonsignificant trend towards lower odds of death in ARDS patients receiving a statin during their ICU admission (OR 0.27, 95% CI 0.06, 1.21; p = 0.09).[ 83 ] However, a recently published retrospective cohort study from the Mayo Clinic (Rochester, MN, USA) showed no difference in mortality or organ dysfunction in ARDS

also in 5,406 other papers

A subsequent multicentre phase III trial of TLC-C-53 in 102 ARDS patients[ 73 ] demonstrated no differences in time to liberation from the ventilator or 28-day mortality; the trend to shorter duration of hypoxaemia in the treatment group failed to reach statistical significance.

also in 6,035 other papers